NanoViricides Inc (NNVC)

[BonelessCat]

How about these two?

12. Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J, Schultz RM. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999;26(2 Suppl 6):55–62.

13. B.A. Teicher, V. Chen, C. Shih, K. Menon, P.A. Forler, V.G. Phares et al., Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 6 3 (2000), pp. 1016–1023. View Record in Scopus | Cited By in Scopus (74)

The preclinical tests above were for Pemetrexed, the base drug in Alimta.

Here is proof of the connection:
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
http://www.ncbi.nlm.nih.gov/pubmed/18455781

No question whatsoever that Menon's claims of being a developer/inventor of Alimta are absolutely true.